[
    [
        {
            "time": "",
            "original_text": "贝达药业：目前CM082针对肾癌适应症的新药注册申报准备工作正在推进中",
            "features": {
                "keywords": [
                    "贝达药业",
                    "CM082",
                    "肾癌",
                    "新药注册"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：目前CM082针对肾癌适应症的新药注册申报准备工作正在推进中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：公司及控股子公司的主营业务为研发、生产、销售具有自主知识产权的创新药产品，暂未对外提供CRO方面的研究服务",
            "features": {
                "keywords": [
                    "贝达药业",
                    "主营业务",
                    "创新药",
                    "CRO"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：公司及控股子公司的主营业务为研发、生产、销售具有自主知识产权的创新药产品，暂未对外提供CRO方面的研究服务",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 4,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：CM082是针对VEGFR和PDGFR靶点的多靶点受体酪氨酸激酶（RTKs）抑制剂，基于对新生血管生成的抑制作用，在前期的临床研究中发现了CM082对于湿性年龄相关性黄斑变性的治疗作用",
            "features": {
                "keywords": [
                    "贝达药业",
                    "CM082",
                    "VEGFR",
                    "PDGFR",
                    "靶点",
                    "临床研究",
                    "黄斑变性"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：CM082是针对VEGFR和PDGFR靶点的多靶点受体酪氨酸激酶（RTKs）抑制剂，基于对新生血管生成的抑制作用，在前期的临床研究中发现了CM082对于湿性年龄相关性黄斑变性的治疗作用",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：板块性价比渐突出 Q3业绩延续较好增长趋势",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "性价比",
                    "Q3业绩",
                    "增长趋势"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：板块性价比渐突出 Q3业绩延续较好增长趋势",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "是否符合第五套上市标准相关要求？益方生物科创板IPO回复这样论证",
            "features": {
                "keywords": [
                    "第五套上市标准",
                    "益方生物",
                    "科创板",
                    "IPO"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "是否符合第五套上市标准相关要求？益方生物科创板IPO回复这样论证",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]